Stereotactic radiosurgery (SRS) is commonly used for the treatment of vestibular schwannomas given its high rate of tumor control and low rate of complications. Facial nerve palsy has been reported several months after treatment as a rare late complication of SRS. Here, we report a case of facial weakness occurring only 4 days after treatment and discuss potential etiology and management considerations.
Introduction
Vestibular schwannomas (VS) are slow-growing brain tumors that can be managed through observation, microsurgical resection, fractionated radiation therapy, stereotactic radiosurgery (SRS), or a combination thereof. [1] The management of VS is typically individualized following a discussion between the patient and provider of the risks and benefits of the various treatment modalities. SRS has become an increasingly utilized treatment for VS given that it is noninvasive and has demonstrated high rates of tumor control. [2] [3] [4] Nonacoustic complications of SRS are fairly rare but include trigeminal nerve dysfunction and facial nerve palsy. [5] Facial nerve dysfunction occurs from 0 to 6% of patients treated with SRS in modern studies with marginal doses of 13 Gy or less. [6, 7] Although transient posttreatment hemifacial spasm occurs in up to 2% of patients, no permanent facial weakness has been seen with hypofractionated SRS consisting of 18 Gy in three fractions or 25 Gy in five fractions. [2, 8] When facial weakness occurs, it is often noted as a late complication occurring over 4 months following SRS. [7] Here, we present a case of a patient with a vestibular schwannoma who was treated with single fraction SRS and developed facial weakness 4 days after his treatment.
Case Report
Following institutional review board approval for a retrospective review of this patient's outcomes, data were collected. The patient initially presented as a review of this case is covered by a Stanford IRB-approved protocol with a history of hypertension, hyperlipidemia, type 2 diabetes mellitus, T-cell lymphoma in remission status postchemotherapy approximately 4 years prior, and left nasal ala basal cell carcinoma status postradiation therapy 3 years prior, who presented with left-sided progressive hearing loss and tinnitus. He had slight gait unsteadiness, but denied vertigo, facial pain, facial weakness, facial numbness, or diplopia. Initial audiometry revealed a speech reception threshold of 50 dB on the left versus 25 dB on the right, and word recognition of 0% at 90 dB on the left versus 100% at 65 dB on the right. An magnetic resonance imaging (MRI) demonstrated a 13 mm × 6 mm vestibular schwannoma in the left internal auditory canal. Following 18 months of observation, serial imaging demonstrated interval growth of the tumor to 16 mm × 9 mm.
On physical examination, the patient had no hearing on the left side. His facial nerve function was fully intact bilaterally. He had a steady gait and was able to tandem walk without difficulty. Our institutional standard is to hypofractionate SRS (18 Gy in 3 fractions) for large schwannomas and those with serviceable hearing. Given
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For reprints contact: reprints@medknow.com his absence of hearing, he received 14 Gy in a single fraction to the 80% isodose line covering the 0.508 cm 3 tumor (conformity inde × 1.24). He tolerated the procedure well, with no unanticipated adverse events.
Four days after radiosurgery, the patient noted left lip numbness and a sensation of left eye swelling. The following day, he woke up with a left facial droop and inability to close his left eye. An MRI displayed a slight increase in size of the Cerebellopontine angle (CPA) portion of the vestibular schwannoma to 10 mm × 8 mm compared to 9 mm × 6 mm pre-SRS with central hypo-intensity along with increased enhancement of the left facial nerve [ Figure 1 ]. He had House-Brackmann (HB) 5/6 left facial weakness, unable to close his eyes, with decreased facial tone and obvious asymmetry. He denied facial numbness. He was started on dexamethasone 4 mg twice a day and valacyclovir for possible radiation-induced viral reactivation.
At 1-month follow-up, his facial droop improved slightly to HB 4/6 with improved, but still incomplete, eye closure, and facial asymmetry. Dexamethasone and valacyclovir were discontinued. At 6 months follow-up, his facial weakness improved to HB 3/6, able to close his eye and with much-improved tone and symmetry. Repeat MRI displayed stable size of the tumor and stable mild asymmetric enhancement of the facial nerve, with a more homogeneous enhancement of the schwannoma as is typically seen following SRS. At 1-year follow-up, his facial weakness continued to improve to HB 2/6 with signs of facial synkinesis manifest as difficulty relaxing his lip without closing his eyes. MRI showed stable size of the vestibular schwannoma and stable asymmetric facial nerve enhancement. At 2 years of follow-up, his left face gradually improved. He had HB 2/6 with largely resolved facial nerve synkinesis. MRI again showed a stable left CPA mass and stable asymmetric enhancement of the facial nerve.
Discussion
SRS is a noninvasive standard of care for the treatment of VS, providing high rates of local control with low rates of complication. While facial weakness is a rare complication of SRS, generally occurring in 0%-6% of patients treated with single fraction SRS, [6, 7] it typically occurs late in the treatment course. We present a case of acute facial weakness occurring days following SRS. This patient developed HB 5/6 facial weakness which improved over several months to HB 2/6. MRI obtained at the first follow-up visit showed slight enlargement of the tumor and enhancement of the facial nerve.
In general, the mechanism of SRS-associated facial weakness is unknown. Similarly, the time frame during which toxicity is seen is not well reported. Although the etiology in this case is uncertain, tumor expansion following SRS may have caused direct compression of the facial nerve resulting in transient paresis. Although tumor swelling and the characteristic imaging changes of central loss of enhancement followed by a return of more homogeneous enhancement pattern are common following SRS, [9] the time point at which these changes are seen is unknown, as we normally obtain the first MRI no sooner than 6 months following treatment. One may hypothesize that the post-SRS swelling is rarely symptomatic due to its development over months. In our patient, it developed within 4 days, with less time for potential compensation of this swelling and resultant facial weakness. Dexamethasone was started in an attempt to relieve any mass effect on the facial nerve.
Alternatively, one may hypothesize that irradiation of the facial nerve may have caused a viral reactivation leading to a Bell's palsy, similar to reactivation of hepatitis B after radiotherapy for hepatobiliary malignancies. [10] Valacyclovir was therefore initiated.
Multiple risk factors for facial nerve toxicity following SRS have been identified, including patient factors such as tumor size >1.5 cm 3 , [6] age >60, [6] prior surgical resection, [11] and dosimetric factors such as brainstem dose, [11] prescription dose, [3, 6, 11] and fractionation of the treatments. [2, [12] [13] [14] Length of cranial nerve irradiated may also increase risk for toxicity as shown in studies of SRS for trigeminal neuralgia. [15] Although the length of nerve irradiation in our patients was short and the tumor volume was small, risk factors for facial nerve toxicity included his age, a slightly higher marginal dose (14 Gy) than what is conventionally prescribed at our institution for single fraction treatments (typically 13 Gy) and, arguably, the use of a single fraction rather than a hypofractionated treatment course. In our series of 383 patients treated with 18 Gy in three fractions, no facial weakness was seen. [2] 
Conclusion
Although facial nerve toxicity following single fraction SRS is typically considered a late side effect, acute toxicity can occur. To the best of our knowledge, the facial weakness seen 4 days following treatment is the earliest reported facial palsy for vestibular schwannoma SRS. Marginal doses of 13 Gy or less in 1 fraction and, potentially, hypofractionation of treatment may decrease the risk of facial nerve toxicity. To minimize cranial nerve toxicity, our practice is to treat the majority of patients with 18 Gy in 3 consecutive days; those with small tumors without serviceable hearing may be treated with 12-13 Gy in a single fraction.
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